RESTATED ISIS PHARMACEUTICALS, INC. 10B5-1 TRADING PLAN10b5-1 Trading Plan • March 31st, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This 10b5-1 Trading Plan, (the "Trading Plan"), between Isis Pharmaceuticals, Inc. ("Isis") and Golden Triangle Securities llc ("Broker"), is entered into on February 22, 2002. Capitalized terms not otherwise defined herein will have the meanings given to them in Exhibit A attached hereto.
AMENDMENTCollaborative Research and License Agreement • March 31st, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment to the Collaborative Research and License Agreement dated July 9, 2001, ("Agreement"), by and between ISIS PHARMACEUTICALS, INC. ("Isis"), a Delaware corporation, with its principal office at 2292 Faraday Avenue, Carlsbad, California 92008 and PE CORPORATION (NY), a New York corporation, through the CELERA GENOMICS GROUP, ("Celera"), having a principal place of business at 45 West Gude Drive, Rockville, Maryland 20850. Celera and Isis may be referred to herein individually as a "Party" and collectively as the "Parties".
AMENDMENT NO. 2Collaborative Research and License Agreement • March 31st, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 2 ("Amendment No. 2") to the Collaborative Research and License Agreement effective July 9, 2001 ("Agreement") is made by and between ISIS PHARMACEUTICALS, INC. ("Isis"), a Delaware corporation, with its principal office at 2292 Faraday Avenue, Carlsbad, California 92008 and APPLERA CORPORATION, a Delaware corporation, through the CELERA GENOMICS GROUP, ("Celera"), having a principal place of business at 45 West Gude Drive, Rockville, Maryland 20850. Celera and Isis may be referred to herein individually as a "Party" and collectively as the "Parties." This Amendment shall be effective as of the date of last signature below by an authorized representative of the Parties.
